Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856627 | 0.98 | HRH3 (0.40) | HTR7HRH3KCNH2DRD3CHRM4 | |
| SCHEMBL4561888 | 0.96 | HRH3 (0.40) | HTR7HRH3KCNH2DRD3CHRM4 | |
| SCHEMBL2852974 | 0.94 | HRH3 (0.42) | HRH3KCNH2CHRM4HTR1ASLC6A4 | |
| SCHEMBL2194852 | 0.87 | DRD3 (0.53) | HTR7DRD3HTR1ADRD2HTR2A | |
| SCHEMBL2191733 | 0.87 | HTR7 (0.50) | HTR7DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL4054287 | 0.86 | HTR7 (0.38) | HTR7HRH3DRD3HTR1ASLC6A2 | |
| SCHEMBL1256145 | 0.85 | HTR1A (0.49) | DRD3HTR1ADRD2HTR2AHRH1 | |
| SCHEMBL2853060 | 0.85 | DRD2 (0.49) | HRH3KCNH2DRD3HTR1ADRD2 | |
| SCHEMBL2195868 | 0.85 | HTR7 (0.47) | HTR7DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL2194249 | 0.85 | DRD3 (0.53) | HTR7DRD3HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598180-B2 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1715921-B1 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | ABRAXIS BIOSCIENCE, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | TPH2, TPH1, GRIK5 | HTR7 114/4885HRH3 807/4885KCNH2 2665/4885 |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | NLN, CYP11B2, GRIN2C | HTR7 59/4885HRH3 837/4885KCNH2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.